肿瘤基础与临床
腫瘤基礎與臨床
종류기출여림상
JOURNAL OF BASIC AND CLINICAL ONCOLOGY
2014年
6期
479-481,482
,共4页
复发性卵巢癌%腹腔热灌注化疗%吉西他滨%顺铂
複髮性卵巢癌%腹腔熱灌註化療%吉西他濱%順鉑
복발성란소암%복강열관주화료%길서타빈%순박
recurrent ovarian cancer%intraperitoneal hyperthermic chemotherapy%gemcitabine%cisplatin
目的：探讨吉西他滨静脉化疗联合顺铂高精度持续循环腹腔热灌注化疗对复发性卵巢癌的临床疗效和安全性。方法55例复发性卵巢癌患者分为2组，观察组28例予顺铂高精度持续循环腹腔热灌注化疗，第5天予吉西他滨+卡铂静脉化疗；对照组27例仅予单纯静脉化疗，21 d为1周期。比较2组肿瘤控制情况、腹腔积液控制情况、KPS评分及毒副反应。结果观察组和对照组患者治疗3周期后的肿瘤控制有效率分别为82.1%、44.4%（P<0.05）；2组腹腔积液控制有效率分别为87.0%、45.0%（P<0.05）；2组KPS评分改善率分别为85.7%、51.9%（P<0.05）。2组患者的毒副反应均可耐受。结论吉西他滨联合顺铂高精度持续循环腹腔热灌注化疗治疗复发性卵巢癌不仅能提高肿瘤控制率，减少腹腔积液，还能显著改善患者生活质量，安全性高。
目的：探討吉西他濱靜脈化療聯閤順鉑高精度持續循環腹腔熱灌註化療對複髮性卵巢癌的臨床療效和安全性。方法55例複髮性卵巢癌患者分為2組，觀察組28例予順鉑高精度持續循環腹腔熱灌註化療，第5天予吉西他濱+卡鉑靜脈化療；對照組27例僅予單純靜脈化療，21 d為1週期。比較2組腫瘤控製情況、腹腔積液控製情況、KPS評分及毒副反應。結果觀察組和對照組患者治療3週期後的腫瘤控製有效率分彆為82.1%、44.4%（P<0.05）；2組腹腔積液控製有效率分彆為87.0%、45.0%（P<0.05）；2組KPS評分改善率分彆為85.7%、51.9%（P<0.05）。2組患者的毒副反應均可耐受。結論吉西他濱聯閤順鉑高精度持續循環腹腔熱灌註化療治療複髮性卵巢癌不僅能提高腫瘤控製率，減少腹腔積液，還能顯著改善患者生活質量，安全性高。
목적：탐토길서타빈정맥화료연합순박고정도지속순배복강열관주화료대복발성란소암적림상료효화안전성。방법55례복발성란소암환자분위2조，관찰조28례여순박고정도지속순배복강열관주화료，제5천여길서타빈+잡박정맥화료；대조조27례부여단순정맥화료，21 d위1주기。비교2조종류공제정황、복강적액공제정황、KPS평분급독부반응。결과관찰조화대조조환자치료3주기후적종류공제유효솔분별위82.1%、44.4%（P<0.05）；2조복강적액공제유효솔분별위87.0%、45.0%（P<0.05）；2조KPS평분개선솔분별위85.7%、51.9%（P<0.05）。2조환자적독부반응균가내수。결론길서타빈연합순박고정도지속순배복강열관주화료치료복발성란소암불부능제고종류공제솔，감소복강적액，환능현저개선환자생활질량，안전성고。
Objective To investigate the clinical efficacy and safety of gemcitabine plus high accurate continuous circulation intraperitoneal hyperthermic chemotherapy of cisplatin for recurrent ovarian cancer. Methods All the 55 patients with recurrent ovarian cancer were divided into 2 groups,28 patients of the observation group received the high accurate continuous circulation intraperitoneal hyperthermic chemotherapy of cisplatin,and then with intrave-nous chemotherapy of gemcitabine and carboplatin on the fifth day;27 patients of the control group received only the intravenous chemotherapy. 21 days were 1 cycle. And then the tumor control rate,the ascitic fluid control rate,KPS scores,and the toxicities were compared between the two groups. Results After 3 circles of treatment,the tumor control effective rates were 82. 1% and 44. 4% in the observation group and the control group respectively( P<0. 05). The ascitic fluid control effective rates were 87. 0% and 45. 0% respectively(P<0. 05). The KPS score improvement rates were 85. 7% and 51. 9% in the observation group and the control group(P<0. 05). The toxici-ties were tolerable for both the two groups. Conclusion Gemcitabine plus high accurate continuous circulation in-traperitoneal hyperthermic chemotherapy of cisplatin can enhance the tumor control rate,reduce the ascitic fluid,sig-nificantly improve the quality of life,and has good safety for recurrent ovarian cancer.
